Literature DB >> 23986445

The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand.

Anfernee Kai-Wing Tse1, Ka-Yu Chow, Hui-Hui Cao, Chi-Yan Cheng, Hiu-Yee Kwan, Hua Yu, Guo-Yuan Zhu, Yiu-Cheong Wu, Wang-Fun Fong, Zhi-Ling Yu.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis and kills cancer cells but not normal cells. However, TRAIL resistance due to low level of TRAIL receptor expression is widely found in cancer cells and hampers its development for cancer treatment. Thus, the agents that can sensitize the tumor cells to TRAIL-mediated apoptosis are urgently needed. We investigated whether tanshinones, the major bioactive compounds of Salvia miltiorrhiza (danshen), can up-regulate TRAIL receptor expression. Among the major tanshinones being tested, cryptotanshinone (CT) showed the best ability to induce TRAIL receptor 2 (DR5) expression. We further showed that CT was capable of promoting TRAIL-induced cell death and apoptosis in A375 melanoma cells. CT-induced DR5 induction was not cell type-specific, as DR5 induction was observed in other cancer cell types. DR5 knockdown abolished the enhancing effect of CT on TRAIL responses. Mechanistically, induction of the DR5 by CT was found to be p53-independent but dependent on the induction of CCAAT/enhancer-binding protein-homologous protein (CHOP). Knockdown of CHOP abolished CT-induced DR5 expression and the associated potentiation of TRAIL-mediated cell death. In addition, CT-induced ROS production preceded up-regulation of CHOP and DR5 and consequent sensitization of cells to TRAIL. Interestingly, CT also converted TRAIL-resistant lung A549 cancer cells into TRAIL-sensitive cells. Taken together, our results indicate that CT can potentiate TRAIL-induced apoptosis through up-regulation of DR5.

Entities:  

Keywords:  Apoptosis; Cell Death; Melanoma; Reactive Oxygen Species (ROS); Trail

Mesh:

Substances:

Year:  2013        PMID: 23986445      PMCID: PMC3795290          DOI: 10.1074/jbc.M113.483909

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene.

Authors:  G S Wu; T F Burns; E R McDonald; W Jiang; R Meng; I D Krantz; G Kao; D D Gan; J Y Zhou; R Muschel; S R Hamilton; N B Spinner; S Markowitz; G Wu; W S el-Deiry
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

2.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

Authors:  R Takimoto; W S El-Deiry
Journal:  Oncogene       Date:  2000-03-30       Impact factor: 9.867

Review 3.  TRAIL receptor signaling and therapeutics.

Authors:  Junaid Abdulghani; Wafik S El-Deiry
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

4.  Tanshinone IIA may inhibit the growth of small cell lung cancer H146 cells by up-regulating the Bax/Bcl-2 ratio and decreasing mitochondrial membrane potential.

Authors:  Chun-Yuan Cheng; Chin-Cheng Su
Journal:  Mol Med Rep       Date:  2010 Jul-Aug       Impact factor: 2.952

Review 5.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Authors:  Thomas K Eigentler; Ulrich M Caroli; Peter Radny; Claus Garbe
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

6.  NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.

Authors:  Cigdem Aydin; Ahter D Sanlioglu; Atil Bisgin; Burcak Yoldas; Levent Dertsiz; Bahri Karacay; Thomas S Griffith; Salih Sanlioglu
Journal:  BMC Cancer       Date:  2010-10-27       Impact factor: 4.430

7.  Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.

Authors:  Yeoun Hee Kim; Eun Mi Jung; Tae-Jin Lee; Sang Hyun Kim; Yung Hyun Choi; Jeen Woo Park; Jong-Wook Park; Kyeong Sook Choi; Taeg Kyu Kwon
Journal:  Free Radic Biol Med       Date:  2007-12-08       Impact factor: 7.376

8.  New therapeutical strategies in the treatment of metastatic disease.

Authors:  Fanny Julia; Luc Thomas; Stéphane Dalle
Journal:  Dermatol Ther       Date:  2012 Sep-Oct       Impact factor: 2.851

9.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.

Authors:  T S Griffith; W A Chin; G C Jackson; D H Lynch; M Z Kubin
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

10.  Involvement of selective reactive oxygen species upstream of proapoptotic branches of unfolded protein response.

Authors:  Makiko Yokouchi; Nobuhiko Hiramatsu; Kunihiro Hayakawa; Maro Okamura; Shuqi Du; Ayumi Kasai; Yosuke Takano; Akihiro Shitamura; Tsuyoshi Shimada; Jian Yao; Masanori Kitamura
Journal:  J Biol Chem       Date:  2007-12-17       Impact factor: 5.157

View more
  19 in total

1.  Sensitization of Melanoma Cells for Death Ligand TRAIL Is Based on Cell Cycle Arrest, ROS Production, and Activation of Proapoptotic Bcl-2 Proteins.

Authors:  Sandra-Annika Quast; Katja Steinhorst; Michael Plötz; Jürgen Eberle
Journal:  J Invest Dermatol       Date:  2015-07-02       Impact factor: 8.551

2.  Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers.

Authors:  Jaekwang Kim; Miyong Yun; Eun-Ok Kim; Deok-Beom Jung; Gunho Won; Bonglee Kim; Ji Hoon Jung; Sung-Hoon Kim
Journal:  Br J Pharmacol       Date:  2016-02-22       Impact factor: 8.739

3.  Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma.

Authors:  Hui-Hui Cao; Jian-Hong Chu; Hiu-Yee Kwan; Tao Su; Hua Yu; Chi-Yan Cheng; Xiu-Qiong Fu; Hui Guo; Ting Li; Anfernee Kai-Wing Tse; Gui-Xin Chou; Huan-Biao Mo; Zhi-Ling Yu
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

4.  Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death.

Authors:  Stefania Raimondo; Flores Naselli; Simona Fontana; Francesca Monteleone; Alessia Lo Dico; Laura Saieva; Giovanni Zito; Anna Flugy; Mauro Manno; Maria Antonietta Di Bella; Giacomo De Leo; Riccardo Alessandro
Journal:  Oncotarget       Date:  2015-08-14

5.  A promising "TRAIL" of tanshinones for cancer therapy.

Authors:  Tsing-Fen Ho; Chia-Che Chang
Journal:  Biomedicine (Taipei)       Date:  2015-11-28

6.  Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity.

Authors:  Jiye Wang; Guangji Zhang; Chunyan Dai; Xiufei Gao; Jianbin Wu; Li Shen; Zhe Chen; Pei Liu
Journal:  J Int Med Res       Date:  2017-01-25       Impact factor: 1.671

7.  Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.

Authors:  Eun Ah Shin; Eun Jung Sohn; Gunho Won; Jeong-Un Choi; Myongsuk Jeong; Bonglee Kim; Min-Jeong Kim; Sung-Hoon Kim
Journal:  Oncotarget       Date:  2014-07-30

8.  Ethanolic extract of Descurainia sophia seeds sensitizes A549 human lung cancer cells to TRAIL cytotoxicity by upregulating death receptors.

Authors:  Jong-Shik Park; Chae Jun Lim; Ok-Sun Bang; No Soo Kim
Journal:  BMC Complement Altern Med       Date:  2016-04-02       Impact factor: 3.659

Review 9.  Roles of Reactive Oxygen Species in Anticancer Therapy with Salvia miltiorrhiza Bunge.

Authors:  Yu-Chiang Hung; Tai-Long Pan; Wen-Long Hu
Journal:  Oxid Med Cell Longev       Date:  2016-08-04       Impact factor: 6.543

Review 10.  Recent insights into the biological activities and drug delivery systems of tanshinones.

Authors:  Yuee Cai; Wenji Zhang; Zirong Chen; Zhi Shi; Chengwei He; Meiwan Chen
Journal:  Int J Nanomedicine       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.